Summary
Pfizer Inc.'s second-quarter 2005 results show a 1% increase in revenue to $12.4 billion, driven by strong performance in its Human Health, Consumer Healthcare, and Animal Health segments, alongside favorable foreign exchange rates. Despite overall revenue growth, the company is navigating patent expirations for key products, impacting growth in certain therapeutic areas. Significant financial events this quarter include a substantial asset impairment charge of $1.2 billion related to the suspension of Bextra sales and a $1.7 billion tax charge related to the repatriation of foreign earnings under the American Jobs Creation Act of 2004. The company is also actively managing its cost structure through the 'Adapting to Scale' initiative, aiming for significant cost savings by 2008, and continuing integration efforts from the Pharmacia acquisition. Pfizer's financial position remains robust, with strong operating cash flow, though working capital has decreased due to dividend payments, share repurchases, and tax provisions. The company reaffirmed its commitment to returning value to shareholders through an increased share repurchase program.
Key Highlights
- 1Total revenues increased 1% to $12.4 billion for the second quarter of 2005 compared to the prior year period.
- 2Recorded a $1.2 billion pre-tax asset impairment charge and related costs due to the suspension of Bextra sales.
- 3Incurred a $1.7 billion income tax charge related to the repatriation of foreign earnings under the American Jobs Creation Act of 2004.
- 4Launched the 'Adapting to Scale' productivity initiative, targeting $4 billion in cost savings by 2008.
- 5Continued integration efforts from the Pharmacia acquisition, expecting $4.2 billion in Pharmacia-related synergies in 2005.
- 6Net cash provided by continuing operating activities increased to $7.0 billion for the first six months of 2005, up from $5.2 billion in the prior year.
- 7Announced a new $5 billion share-purchase plan authorized by the Board of Directors.